Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 9

PMID 35804968

Authors

Edoardo Crimini

Matteo Repetto

Paolo Tarantino

Liliana Ascione

Gabriele Antonarelli

Elena Guerini Rocco

Massimo Barberis

Luca Mazzarella

Giuseppe Curigliano

Affiliations

Soon will be listed here.

Abstract

Considering the rapid improvement of cancer drugs' efficacy and the discovery of new molecular targets, the formulation of therapeutical indications based on the multidisciplinary approach of MTB is becoming increasingly important for attributing the correct salience to the targets identified in a single patient. Nevertheless, one of the biggest stumbling blocks faced by MTBs is not the bare indication, but its implementation in the clinical practice. Indeed, administering the drug suggested by MTB deals with some relevant difficulties: the economical affordability and geographical accessibility represent some of the major limits in the patient's view, while bureaucracy and regulatory procedures are often a disincentive for the physicians. In this review, we explore the current literature reporting MTB experiences and precision medicine clinical trials, focusing on the challenges that authors face in applying their therapeutical indications. Furthermore, we analyze and discuss some of the solutions devised to overcome these difficulties to support the MTBs in finding the most suitable solution for their specific situation. In conclusion, we strongly encourage regulatory agencies and pharmaceutical companies to develop effective strategies with medical centers implementing MTBs to facilitate access to innovative drugs and thereby allow broader therapeutical opportunities to patients.

Citing Articles

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.

Melosky B, Juergens R, Banerji S, Sacher A, Wheatley-Price P, Snow S Ther Adv Med Oncol. 2025; 17():17588359241308784.

PMID: 39776537 PMC: 11705342. DOI: 10.1177/17588359241308784.

The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit.

Esposito A, Crimini E, Criscitiello C, Belli C, Scafetta R, Scalia R Cancers (Basel). 2025; 16(24.

PMID: 39766151 PMC: 11674575. DOI: 10.3390/cancers16244252.

Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.

Masucci M, Karlsson C, Blomqvist L, Ernberg I J Pers Med. 2024; 14(6).

PMID: 38929782 PMC: 11204735. DOI: 10.3390/jpm14060561.

Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.

Kraus F, Sultova E, Heinrich K, Jung A, Westphalen C, Tauber C Int J Mol Sci. 2024; 25(4).

PMID: 38397025 PMC: 10888648. DOI: 10.3390/ijms25042345.

Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.

Sotelo-Rodriguez C, Vallejo-Ardila D, Ruiz-Patino A, Chamorro D, Rodriguez J, Moreno-Perez D JCO Glob Oncol. 2024; 10:e2300011.

PMID: 38237094 PMC: 10805441. DOI: 10.1200/GO.23.00011.

References

Ahn E, Mangat P, Garrett-Mayer E, Halabi S, Dib E, Haggstrom D . Palbociclib in Patients With Non-Small-Cell Lung Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2022; 4:757-766. DOI: 10.1200/PO.20.00037. View

Tuxen I, Rohrberg K, Oestrup O, Ahlborn L, Schmidt A, Spanggaard I . Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. Clin Cancer Res. 2018; 25(4):1239-1247. DOI: 10.1158/1078-0432.CCR-18-1780. View

Rodon J, Soria J, Berger R, Miller W, Rubin E, Kugel A . Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019; 25(5):751-758. PMC: 6599610. DOI: 10.1038/s41591-019-0424-4. View

Friedman C, Hainsworth J, Kurzrock R, Spigel D, Burris H, Sweeney C . Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discov. 2021; 12(3):654-669. PMC: 9394388. DOI: 10.1158/2159-8290.CD-21-0450. View

Varnier R, Le Saux O, Chabaud S, Garin G, Sohier E, Wang Q . Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. Eur J Cancer. 2019; 118:156-165. DOI: 10.1016/j.ejca.2019.06.017. View

Unger J, Cook E, Tai E, Bleyer A . The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book. 2016; 35:185-98. PMC: 5495113. DOI: 10.1200/EDBK_156686. View

Galsky M, Stensland K, McBride R, Latif A, Moshier E, Oh W . Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med. 2014; 175(2):293-5. DOI: 10.1001/jamainternmed.2014.6300. View

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Herzog T . Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?. Oncotarget. 2018; 9(10):9456-9467. PMC: 5823623. DOI: 10.18632/oncotarget.24258. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

10.

Pishvaian M, Blais E, Bender R, Rao S, Boca S, Chung V . A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open. 2020; 2(4):505-515. PMC: 6994017. DOI: 10.1093/jamiaopen/ooz045. View

11.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

12.

Meropol N, Buzaglo J, Millard J, Damjanov N, Miller S, Ridgway C . Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw. 2007; 5(8):655-64. DOI: 10.6004/jnccn.2007.0067. View

13.

Pantziarka P, Capistrano I R, De Potter A, Vandeborne L, Bouche G . An Open Access Database of Licensed Cancer Drugs. Front Pharmacol. 2021; 12:627574. PMC: 7991999. DOI: 10.3389/fphar.2021.627574. View

14.

Moore T, Heyward J, Anderson G, Alexander G . Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study. BMJ Open. 2020; 10(6):e038863. PMC: 7295430. DOI: 10.1136/bmjopen-2020-038863. View

15.

Flaherty K, Gray R, Chen A, Li S, Patton D, Hamilton S . The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020; 112(10):1021-1029. PMC: 7566320. DOI: 10.1093/jnci/djz245. View

16.

Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E . Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020; 11(1):4965. PMC: 7532150. DOI: 10.1038/s41467-020-18613-3. View

17.

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

18.

Rothwell D, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E . Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019; 25(5):738-743. DOI: 10.1038/s41591-019-0380-z. View

19.

Baghdadi T, Garrett-Mayer E, Halabi S, Mangat P, Rich P, Ahn E . Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020; 15(6):743-750. DOI: 10.1007/s11523-020-00752-8. View

20.

Tredan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardiere A, Fayette J . Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol. 2019; 30(5):757-765. DOI: 10.1093/annonc/mdz080. View